Single-center fase 2-3 trial of gallium-68-RM2 PET-MRI for evaluation of patients with biochemical recurrence of prostate cancer
NCCN guidelines include PSMA-targeted PET for detection of biochemical recurrence of prostate cancer. However, targeting a single tumor characteristic might not be sufficient to reflect the full extent of disease Gastrin releasing peptide receptors (GRPR) have been show to be overexpressed in prostate cancer. A phase 2-3 trial at Stanford University (Stanford, CA) evaluated the diagnostic performance of the GRPR-targeting radiopharmaceutical 68Ga-RM2 in patients with biochemical recurrence or prostate cancer. Among 100 patients, 68Ga-RM2 PET-MRI was positive in 69 patients, while MRI alone was positive in 40 patients (p<0.0001). In a per-lesion analysis 68GA-RM2 PET-MRI showed significantly higher detection rate than MRI alone (143 versus 96 lesions; p<0.0001). The authors conclude that 68Ga-RM2 PET-MRI showed better diagnostic performance than MRI alone in patients with biochemical recurrence of prostate cancer.